Phase II study evaluating the safety and efficacy of neratinib and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors: KCSG AL20‐17/KM23 trial
Year: 2025
Type: article
Abstract: Y
Source: 癌症：英文版
DOI: 10.1002/cac2.70026
Authors: Kyoungmin Lee, Kyung‐Hun Lee, Dong‐Wan Kim, Jeesun Yoon, Yoon Ji Choi, Soohyeon Lee, Ju Won Kim, Kyong Hwa Park, Wonyoung Choi, Youngjoo Lee, Hyewon Ryu, Dong‐Hoe Koo, YunGyoo Lee, Hei‐Cheul Jeung, Min‐Young Lee, Namsu Lee, Myoung Joo Kang, Jieun Lee, Sook Hee Hong, Eun Joo Kang, In Hae Park
Institutions: Seoul National University, Korea University, Seoul National University Hospital, Korea University Guro Hospital, Korea University Anam Hospital, National Cancer Center, National Cancer Center Hospital, Kangbuk Samsung Hospital, Sungkyunkwan University, Chungnam National University, Chungnam National University Hospital, Yonsei University, Gangnam Severance Hospital, Soonchunhyang University, Soonchunhyang University Hospital Seoul, Inje University Haeundae Paik Hospital, Catholic University of Korea
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,080
Awards: G1889613995, G4235315365
OpenAlex ID: W4409370552